rly-4008
relay therapeutics
['rly-4008', 'fgfr2 inhibitor']
dear colleagues an honor for and to bring you our faculty with a simultaneous publication in cancer discovery with the #asco23 clinical science symposium meeting. rly-4008, the first highly selective fgfr2 inhibitor with 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨